<DOC>
	<DOCNO>NCT01495221</DOCNO>
	<brief_summary>This open label study evaluate intravitreally administer 2.0 mg intravitreal aflibercept injection patient previously treat AMD persistent recurrent fluid despite monthly intravitreal anti-VEGF therapy .</brief_summary>
	<brief_title>To Evaluate tHe rOle Intravitreal Aflibercept Injection ( 2.0 mg ) Management previousLy Treated Patients With Exudative AMD</brief_title>
	<detailed_description />
	<criteria>Ability provide write informed consent comply study assessment full duration study Age &gt; 50 year Choroidal neovascularization secondary AMD Best correct visual acuity study eye 20/25 20/400 use ETDRS chart Documentation presence subretinal fluid and/or cystoid macular edema SDOCT follow least four antiVEGF treatment within six month enrollment maximum 5 year year treatment neovascular AMD Documentation presence subretinal fluid and/or cystoid macular edema le 30 day since last treatment Pregnancy ( positive pregnancy test ) lactation Premenopausal woman use adequate contraception . The following consider effective mean contraception : surgical sterilization use oral contraceptive , barrier contraception either condom diaphragm conjunction spermicidal gel , IUD , contraceptive hormone implant patch . Participation another simultaneous medical investigation trial Prior treatment antiVEGF therapy study eye within 30 day BSL Prior treatment PDT within past 3 month 4 prior PDT treatment . Presence significant subfoveal fibrosis atrophy . Prior treatment intravitreal aflibercept injection Prior treatment triamcinolone study eye within 6 month BSL . Prior treatment dexamethasone study eye within 30 day prior BSL Intraocular surgery ( include cataract surgery ) study eye within 2 month precede BSL History vitrectomy surgery , submacular surgery , surgical intervention AMD study eye Active intraocular inflammation ( grade trace ) study eye Current vitreous hemorrhage study eye History rhegmatogenous retinal detachment macular hole ( Stage 3 4 ) study eye Ocular periocular infection Active severe intraocular inflammation Uncontrolled glaucoma study eye ( defined IOP â‰¥ 30 mmHg despite treatment antiglaucoma medication ) History cerebral vascular accident , myocardial infarction , transient ischemic attack within 3 month study enrollment . History allergy fluorescein , ICG iodine , amenable treatment Known hypersensitivity aflibercept excipients</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>